• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Carl Zeiss Meditec adds surgical devices

Article

Carl Zeiss Meditec unveiled new optical coherence tomography (OCT) technology, two surgical ophthalmic microscopes, and two new IOLs at the annual meeting of the European Society of Cataract and Refractive Surgeons in Stockholm, Sweden.

Jena, Germany-Carl Zeiss Meditec unveiled new optical coherence tomography (OCT) technology, two surgical ophthalmic microscopes, and two new IOLs at the annual meeting of the European Society of Cataract and Refractive Surgeons in Stockholm, Sweden.

The OCT technology (Cirrus HD-OCT) is contact-free and uses the interference of light waves for two- or three-dimensional display of tissue structures with high-depth resolution. The spectral domain system offers faster cross-sectional images of the retina with higher resolution, according to the company.

The microscopes (OPMI Lumera, OPMI Lumera T) incorporate stereo coaxial illumination technology to enable surgeons to recognize details of the human eye with a high level of visualization and clarity. The company expects this ability to be especially helpful in the treatment of advanced cases of cataract in which the natural lens of the eye is severely clouded.

The company also plans to launch a femtosecond laser (VisuMax) by the end of the year. Surgeons will be able to use the laser as a separate unit or in combination with the company's excimer laser (MEL 80). Clinical studies have demonstrated a high degree of accuracy in flap incisions, further increasing the level of safety of LASIK treatments and providing the basis for a new surgical method to correct visual defects, according to the company.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.